Trials / Unknown
UnknownNCT03972722
Study of GLS-010 Injection in Patients With Recurrent or Metastatic Cervical Cancer
An Open, Multi-center, Single-arm Phase II Clinical Study to Evaluate the Efficacy and Safety of Recombinant Fully Human Anti-PD-1 Monoclonal Antibody (GLS-010 Injection) in Patients With Recurrent or Metastatic Cervical Cancer
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 89 (estimated)
- Sponsor
- Guangzhou Gloria Biosciences Co., Ltd. · Industry
- Sex
- Female
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Patients with recurrent or metastatic cervical cancer，and will be treated with GLS-010.
Detailed description
Open, uncontrolled, multi-center, phase II study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GLS-010 | Patients will be given 240mg GLS-010 every treatment. |
Timeline
- Start date
- 2019-05-15
- Primary completion
- 2022-05-15
- Completion
- 2023-05-15
- First posted
- 2019-06-04
- Last updated
- 2019-06-05
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03972722. Inclusion in this directory is not an endorsement.